3-(5-{(E)-[2-(naphthalen-1-ylacetyl)hydrazinylidene]methyl}furan-2-yl)benzoic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 3-(5-{(E)-[2-(naphthalen-1-ylacetyl)hydrazinylidene]methyl}furan-2-yl)benzoic acid
• 英文别名: 3-[5-[(E)-[(2-naphthalen-1-ylacetyl)hydrazinylidene]methyl]furan-2-yl]benzoic acid
• 化学式: C₂₄H₁₈N₂O₄
• 分子量: 398.4
• InChiKey: VCSFIXAKTKACBL-MFKUBSTISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.04
• 拓扑面积：
  91.9
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• Method of inhibiting DYRK1B
  申请人：4 SC AG

  公开号：US10633369B2

  公开（公告）日：2020-04-28

  The present invention relates to a DYRK1B inhibitor for use in the treatment of cancer, wherein in said cancer and/or in cells of said cancer the hedgehog signaling pathway is activated, and in particular the activation of the hedgehog signaling pathway is independent of signaling by the G protein-coupled receptor Smoothened.

  本发明涉及一种用于治疗癌症的 DYRK1B 抑制剂，在所述癌症和/或所述癌症细胞中，刺猬信号通路被激活，尤其是刺猬信号通路的激活与 G 蛋白偶联受体 Smoothened 的信号转导无关。
• METHOD OF INHIBITING DYRK1B
  申请人：4SC DISCOVERY GMBH

  公开号：US20140371251A1

  公开（公告）日：2014-12-18

  The present invention relates to a DYRK1B inhibitor for use in the treatment of cancer, wherein in said cancer and/or in cells of said cancer the hedgehog signaling pathway is activated, and in particular the activation of the hedgehog signaling pathway is independent of signaling by the G protein-coupled receptor Smoothened.
• US9951050B2
  申请人：——

  公开号：US9951050B2

  公开（公告）日：2018-04-24